| __timestamp | CymaBay Therapeutics, Inc. | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 15746000 |
| Thursday, January 1, 2015 | 8871000 | 13392000 |
| Friday, January 1, 2016 | 9645000 | 9290000 |
| Sunday, January 1, 2017 | 12387000 | 7672000 |
| Monday, January 1, 2018 | 14381000 | 15293000 |
| Tuesday, January 1, 2019 | 19238000 | 22648000 |
| Wednesday, January 1, 2020 | 17425000 | 21864000 |
| Friday, January 1, 2021 | 23040000 | 37318000 |
| Saturday, January 1, 2022 | 25116000 | 48130000 |
| Sunday, January 1, 2023 | 51953000 | 108146000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Madrigal Pharmaceuticals, Inc. and CymaBay Therapeutics, Inc. have shown distinct strategies in optimizing these costs. From 2014 to 2023, Madrigal's SG&A expenses surged by approximately 587%, peaking in 2023. In contrast, CymaBay's expenses increased by about 535% over the same period. Notably, Madrigal's expenses consistently outpaced CymaBay's, reflecting a more aggressive investment in administrative functions. However, both companies experienced significant jumps in 2023, with Madrigal's expenses reaching nearly double those of CymaBay. This trend highlights the dynamic nature of the biotech industry, where strategic financial management can be as critical as scientific innovation. As these companies continue to evolve, their ability to balance SG&A costs with growth ambitions will be pivotal.
Selling, General, and Administrative Costs: Sanofi vs CymaBay Therapeutics, Inc.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: Madrigal Pharmaceuticals, Inc. vs Opthea Limited Trends and Insights
Selling, General, and Administrative Costs: Madrigal Pharmaceuticals, Inc. vs Verona Pharma plc
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
Madrigal Pharmaceuticals, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Xenon Pharmaceuticals Inc. Trends and Insights
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Evotec SE